Trial reportJournal of clinical hypertension (Greenwich, Conn.)2018
Blood pressure variability predicts adverse events and cardiovascular outcomes in SPRINT.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Blood Pressure Variability and Outcomes Across Antihypertensive Regimens.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Systolic and diastolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension and pre-frailty or frailty status.Journal of clinical hypertension (Greenwich, Conn.) · 2024Trial
- Refining determinants of associations of visit-to-visit blood pressure variability with cardiovascular risk: results from the Action to Control Cardiovascular Risk in Diabetes Trial.Journal of hypertension · 2021Trial
- Carbidopa for Afferent Baroreflex Failure in Familial Dysautonomia: A Double-Blind Randomized Crossover Clinical Trial.Hypertension (Dallas, Tex. : 1979) · 2020Trial
- Blood pressure variability predicts adverse events and cardiovascular outcomes in SPRINT.Journal of clinical hypertension (Greenwich, Conn.) · 2018Trial
- Article
- Orthostatic Blood Pressure, Cardiovascular Disease, and Hypotensive Events.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Associations between gut microbiome and 24-hour blood pressure variability: a cross-sectional study highlighting sex differences and potential therapeutic targets.Gut microbiome (Cambridge, England) · 2026Article
- Association of Blood Pressure Variability with Contrast Nephropathy in STEMI Patients Undergoing Primary PCI.Acta Cardiologica Sinica · 2025Article
- The Association Between Short-Term Blood Pressure Variability and Inflammation in Healthy Young Adults.Journal of cardiovascular development and disease · 2025Article
- Impact of the National Essential Public Health Service Package on Blood Pressure Control in Chinese People With Hypertension: Retrospective Population-Based Longitudinal Study.JMIR public health and surveillance · 2025Article
- The effect of visit-to-visit blood pressure variability on cognitive function: state-of the-art.Cerebral circulation - cognition and behavior · 2025Article
- Hemodynamic phenotypes in chronic kidney disease patients based on linear regression of blood pressure parameters.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Cardiovascular Precision Medicine and Remote Intervention Trial Rationale and Design.Journal of clinical medicine · 2024Article
- Article
- Article
- Article
- Visit-to-visit blood pressure variability is common in primary care patients: Retrospective cohort study of 221,803 adults.PloS one · 2021Article
- Prognostic importance of long-term SBP variability in high-risk hypertension.Journal of hypertension · 2020Article
- Cardiovascular Risk Factors: It's Time to Focus on Variability!Journal of lipid and atherosclerosis · 2020Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SPRINT (Systolic Blood Pressure Intervention Trial) highlighted the benefits of intensive targeted antihypertensive therapy but resulted in higher rates of treatment-related adverse events. Blood pressure (BP) variability has emerged as a significant predictor of outcomes over and above levels of BP. Using the SPRINT data set, we aimed to determine the relationship of BP variability with cardiovascular outcomes and side effects of antihypertensive therapy. The analyses included all participants randomized in SPRINT who reached the target systolic BP (SBP) for their respective groups (intensive < 120 mm Hg; standard < 140 mm Hg). Coefficients of variation (CV) for SBP, diastolic BP (DBP), and PP for each patient characterized variability. Student t test was used to compare treatment arms for each CV metric. Cox proportional hazards regression was used to identify independent predictors of the SPRINT primary outcome and adverse events. P < .15 on univariate analysis was required to enter the model and P < .05 to remain in it. A total of 8884 patients (4561 standard group; 4323 intensive group) met inclusion criteria. DBP CV differed between the groups (9.12 ± 3.20 standard group; 9.47 ± 3.49 intensive group [P < .0001]). DBP CV predicted a greater hazard for the primary outcome (hazard ratio [HR], 1.14) in the overall model as well as separate analyses by treatment arms (standard group HR, 1.15; intensive group HR, 1.19), each P < .0001. DBP CV also independently predicted a greater hazard for acute kidney injury (HR, 1.12) and hypotensive events (HR, 1.12). Visit-to-visit DBP variability independently predicted worse cardiovascular outcomes and hypoperfusion-related adverse events in SPRINT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.